Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial

British Journal of Cancer

Volumn 102, Issue 4, 2010, Pages 673-677

  Joerger, M ^a   Huitema, A D R ^b   Krahenbuhl S ^c   Schellens, J H M ^d,e   Cerny, T ^a   Reni, M ^f   Zucca, E ^g   Cavalli, F ^g   Ferreri, A J M ^f  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

CNS lymphoma; Cytarabine; High dose chemotherapy; Methotrexate; Pharmacokinetics

Indexed keywords

CYTARABINE; FOLINIC ACID; METHOTREXATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 76949102253     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605559     Document Type: Article

References (16)

1. Beal Sl Sheiner LB (1998) NONMEM User's Guide. NONMEM Project Group, University of San Francisco San Francisco C. .A.
2. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4): 1244
3. Evans WE, Christensen ML (1985) Drug interactions with methotrexate. J Rheumatol 12(SUPPL. 12): 15-20
4. Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E, Koren G (1990) Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 117(5): 823-826
5. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2003a) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21(12): 2407-2414, doi:10.1200/JCO.2003.01.135 [doi];JCO.2003.01.135 [pii] (Pubitemid 46621879)
6. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F (2003b) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2): 266-272
7. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90(2): 353-358
8. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58(10): 1513-1520
9. Ferreri AJM, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabra MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Gelemur M, Aondio GM, Avvisati G, Balzarotti M, Brandes A, Costa MJ, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Angelopoulou M, Tirindelli M, Naso V, Franzin A, Anzalone N, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial. Lancet 374(9700): 1512-1520, doi:10.1016/S0140-6736(09)61416-61421
10. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH (2006) Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infu-sional therapy to cancer patients. Br J Clin Pharmacol 62(1): 71-80 (Pubitemid 44195244)
11. Reid T, Yuen A, Catolico M, Carlson RW (1993) Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 33(1): 82-84
12. Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8(3): 227-234
13. Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV, Pla JM (1993) Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 15(5): 375-379
14. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H (2002) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302(2): 666-671
15. Thyss A, Milano G, Kubar J, Namer M, Schneider M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1(8475): 256-258
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3): 176-181, doi:S1053-4296(03)00031-6 [pii];10.1016/S1053- 4296(03)00031-36 [doi] (Pubitemid 36962641)